NKTR – Nektar Therapeutics
Nektar TherapeuticsNKTR
$37.78Name : Nektar Therapeutics
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,289,922,176.00
EPSttm : -18.96
Nektar Therapeutics
$37.78
0.12%$0.045
NKTR — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
21.17
Margin Of Safety %
Put/Call OI Ratio
0.29
EPS Next Q Diff
-1.53
EPS Last/This Y
1.65
EPS This/Next Y
-2.42
Price
37.79
Target Price
133.08
Analyst Recom
1.53
Performance Q
-50.31
Upside
-330.5%
Beta
1.42
Ticker: NKTR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | NKTR | 39.83 | 0.27 | 1.58 | 56879 |
| 2026-10-13 | NKTR | 37.92 | 0.26 | 1.87 | 56543 |
| 2026-10-14 | NKTR | 36.69 | 0.25 | 0.49 | 56573 |
| 2026-10-15 | NKTR | 37.74 | 0.25 | 0.57 | 56787 |
| 2026-10-16 | NKTR | 35.76 | 0.22 | 1.66 | 56813 |
| 2026-10-19 | NKTR | 36.59 | 0.32 | 0.16 | 37909 |
| 2026-10-20 | NKTR | 39.03 | 0.31 | 0.43 | 39087 |
| 2026-10-21 | NKTR | 38.3 | 0.31 | 0.47 | 39702 |
| 2026-10-22 | NKTR | 38.61 | 0.31 | 1.30 | 40649 |
| 2026-10-23 | NKTR | 37.24 | 0.31 | 0.11 | 40872 |
| 2026-10-26 | NKTR | 37.43 | 0.31 | 0.04 | 41042 |
| 2026-10-27 | NKTR | 37.97 | 0.31 | 0.23 | 41036 |
| 2026-10-28 | NKTR | 38.55 | 0.31 | 0.05 | 41066 |
| 2026-10-29 | NKTR | 39.19 | 0.31 | 0.37 | 41159 |
| 2026-10-30 | NKTR | 38.87 | 0.31 | 0.90 | 41407 |
| 2026-11-02 | NKTR | 36.93 | 0.32 | 0.51 | 41751 |
| 2026-11-03 | NKTR | 37.8 | 0.32 | 0.03 | 42412 |
| 2026-11-04 | NKTR | 38.47 | 0.31 | 0.01 | 42753 |
| 2026-11-05 | NKTR | 36.12 | 0.31 | 0.83 | 43448 |
| 2026-11-06 | NKTR | 37.2 | 0.30 | 0.48 | 43324 |
| 2026-11-09 | NKTR | 37.78 | 0.29 | 1.59 | 43332 |
| 2026-11-10 | NKTR | 37.77 | 0.29 | 0.00 | 43269 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | NKTR | 39.84 | -15.9 | - | -8.09 |
| 2026-10-13 | NKTR | 37.98 | -15.9 | - | -8.09 |
| 2026-10-14 | NKTR | 36.88 | -15.9 | - | -8.09 |
| 2026-10-15 | NKTR | 37.71 | -15.9 | - | -8.09 |
| 2026-10-16 | NKTR | 35.79 | -12.9 | - | -8.08 |
| 2026-10-19 | NKTR | 36.59 | -12.9 | - | -8.08 |
| 2026-10-20 | NKTR | 36.59 | -12.9 | - | -8.08 |
| 2026-10-21 | NKTR | 39.26 | -12.9 | - | -8.08 |
| 2026-10-22 | NKTR | 38.61 | -12.9 | - | -8.08 |
| 2026-10-23 | NKTR | 37.21 | -12.9 | - | -8.08 |
| 2026-10-26 | NKTR | 37.46 | -12.9 | - | -8.08 |
| 2026-10-27 | NKTR | 37.97 | -12.9 | - | -8.08 |
| 2026-10-28 | NKTR | 38.56 | -12.9 | - | -8.08 |
| 2026-10-29 | NKTR | 39.23 | -12.9 | - | -8.08 |
| 2026-10-30 | NKTR | 38.88 | -12.9 | - | -8.08 |
| 2026-11-02 | NKTR | 36.96 | -12.9 | - | -8.08 |
| 2026-11-03 | NKTR | 37.78 | -12.9 | - | -8.08 |
| 2026-11-04 | NKTR | 38.46 | -12.9 | - | -8.08 |
| 2026-11-05 | NKTR | 36.21 | -12.9 | - | -8.08 |
| 2026-11-06 | NKTR | 37.24 | -12.9 | - | -8.08 |
| 2026-11-09 | NKTR | 37.79 | -12.9 | - | -8.08 |
| 2026-11-10 | NKTR | 37.79 | -12.9 | - | -8.08 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | NKTR | -2.88 | 31.48 | 21.08 |
| 2026-10-13 | NKTR | -2.88 | 31.48 | 21.08 |
| 2026-10-14 | NKTR | -2.88 | 31.48 | 21.08 |
| 2026-10-15 | NKTR | -2.88 | 31.48 | 21.08 |
| 2026-10-16 | NKTR | -2.88 | 31.48 | 21.08 |
| 2026-10-19 | NKTR | -2.88 | 30.15 | 21.08 |
| 2026-10-20 | NKTR | -2.88 | 30.15 | 21.08 |
| 2026-10-21 | NKTR | -2.88 | 30.15 | 21.08 |
| 2026-10-22 | NKTR | -2.88 | 30.15 | 21.08 |
| 2026-10-23 | NKTR | -2.88 | 30.15 | 21.08 |
| 2026-10-26 | NKTR | -2.88 | 29.50 | 21.08 |
| 2026-10-27 | NKTR | -2.88 | 29.50 | 21.17 |
| 2026-10-28 | NKTR | -2.88 | 29.50 | 21.17 |
| 2026-10-29 | NKTR | -2.88 | 29.50 | 21.17 |
| 2026-10-30 | NKTR | -2.88 | 29.50 | 21.17 |
| 2026-11-02 | NKTR | -2.88 | 29.76 | 21.17 |
| 2026-11-03 | NKTR | -2.88 | 29.76 | 21.17 |
| 2026-11-05 | NKTR | -2.88 | 29.76 | 21.17 |
| 2026-11-06 | NKTR | -2.88 | 29.76 | 21.17 |
| 2026-11-09 | NKTR | -2.88 | 28.94 | 21.17 |
| 2026-11-10 | NKTR | -2.88 | 28.94 | 21.17 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.23
Avg. EPS Est. Current Quarter
-2.07
Avg. EPS Est. Next Quarter
-2.76
Insider Transactions
-2.88
Institutional Transactions
28.94
Beta
1.42
Average Sales Estimate Current Quarter
10
Average Sales Estimate Next Quarter
10
Fair Value
Quality Score
53
Growth Score
30
Sentiment Score
40
Actual DrawDown %
84.2
Max Drawdown 5-Year %
-97.3
Target Price
133.08
P/E
Forward P/E
PEG
P/S
23.63
P/B
1.43
P/Free Cash Flow
EPS
-6.7
Average EPS Est. Cur. Y
-8.08
EPS Next Y. (Est.)
-10.5
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-287.84
Relative Volume
0.36
Return on Equity vs Sector %
-43.7
Return on Equity vs Industry %
-24
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
◆
NKTR
Healthcare
$37.78
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
38.3
Range 1M
40.3%
Sup Dist
2.4%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
16.9%
EPS NY
-30%
52W%
5.8%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+252.2% upside
Upside
+252.2%
Quality
53
NKTR — P/E HistoricalBiotechnology
Nektar TherapeuticsSector: Healthcare
Industry: Biotechnology
Employees: 63
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
NKTR
Latest News
—
Caricamento notizie per NKTR…
stock quote shares NKTR – Nektar Therapeutics Stock Price stock today
news today NKTR – Nektar Therapeutics stock forecast ,stock prediction 2023 2024 2025
marketwatch NKTR – Nektar Therapeutics yahoo finance google finance
stock history NKTR – Nektar Therapeutics invest stock market
stock prices NKTR premarket after hours
ticker NKTR fair value insiders trading